Cargando…

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors

Human regulatory T cells (Tregs) are essential in maintaining immunological tolerance and suppress effector T cells. Tregs are commonly up-regulated in chronic infectious diseases such as tuberculosis (TB) and human immunodeficiency virus (HIV) infection and thereby hamper disease-specific immune re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lieske, Nora V., Tonby, Kristian, Kvale, Dag, Dyrhol-Riise, Anne M., Tasken, Kjetil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636186/ https://www.ncbi.nlm.nih.gov/pubmed/26544592 http://dx.doi.org/10.1371/journal.pone.0141903

Ejemplares similares

The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
por: Tonby, Kristian, et al.
Publicado: (2016)

IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
por: Tonby, Kristian, et al.
Publicado: (2015)

Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
por: Jøntvedt Jørgensen, Marthe, et al.
Publicado: (2021)

Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial
por: Prebensen, Christian, et al.
Publicado: (2017)

Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection
por: Feruglio, S L, et al.
Publicado: (2015)

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
por: Jenum, Synne, et al.
Publicado: (2021)

Regulation of Gag- and Env-Specific CD8(+) T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy
por: Prebensen, Christian, et al.
Publicado: (2016)

Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses
por: Feruglio, Siri L., et al.
Publicado: (2013)

Monocytic myeloid‐derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase‐2 inhibitors
por: Jøntvedt Jørgensen, Marthe, et al.
Publicado: (2020)

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
por: Brekke, Kristin, et al.
Publicado: (2017)

DIAGNOSTIC ACCURACY AND ADDED VALUE OF INFECTION BIOMARKERS IN PATIENTS WITH POSSIBLE SEPSIS IN THE EMERGENCY DEPARTMENT
por: Christensen, Erik E., et al.
Publicado: (2022)

Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease
por: Nore, Kristin Grotle, et al.
Publicado: (2020)

Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4(+) T Cells in HIV-Infected Immunological Non-Responders
por: Lorvik, Kristina Berg, et al.
Publicado: (2021)

Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
por: Mortensen, Rasmus, et al.
Publicado: (2019)

A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries
por: Chendi, Bih H., et al.
Publicado: (2021)

Mycobacterial antigens in pleural fluid mononuclear cells to diagnose pleural tuberculosis in HIV co-infected patients
por: Mustafa, Tehmina, et al.
Publicado: (2020)

Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results
por: Gran, Gerd, et al.
Publicado: (2013)

Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls
por: Wergeland, Ida, et al.
Publicado: (2016)

HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study
por: Pullar, Nadine Durema, et al.
Publicado: (2014)

SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity
por: Mohn, Kristin G-I, et al.
Publicado: (2023)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON(® )TB-Gold interferon-gamma assay
por: Baba, Kamaldeen, et al.
Publicado: (2008)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

Human Immunodeficiency Virus–Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction
por: Meyer-Myklestad, Malin Holm, et al.
Publicado: (2020)

Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting
por: Jørstad, Melissa Davidsen, et al.
Publicado: (2019)

Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country
por: Dyrhol-Riise, Anne M, et al.
Publicado: (2010)

Use of interferon gamma-based assay to diagnose tuberculosis infection in health care workers after short term exposure
por: Storla, Dag Gundersen, et al.
Publicado: (2009)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

MPT64 antigen detection test improves routine diagnosis of extrapulmonary tuberculosis in a low-resource setting: A study from the tertiary care hospital in Zanzibar
por: Jørstad, Melissa Davidsen, et al.
Publicado: (2018)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
por: Thomas, Kubin, et al.
Publicado: (2020)

The MEK5/ERK5 Pathway in Health and Disease
por: Paudel, Rupesh, et al.
Publicado: (2021)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting
por: Hoel, Ida Marie, et al.
Publicado: (2019)

Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4(+) recovery
por: Stiksrud, Birgitte, et al.
Publicado: (2019)

Diagnosis of extrapulmonary tuberculosis using the MPT64 antigen detection test in a high-income low tuberculosis prevalence setting
por: Hoel, Ida Marie, et al.
Publicado: (2020)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gs5rn41bb94esajubmvuva1mqp